Beta Bionics Inc (BBNX) - רווח נקי למניה (EPS TTM)

Net income per share over 12 months from GURU.Markets is used for the analysis, where the -1.84 metric serves as the target level. Beta Bionics Inc (BBNX) develops iLet systems in collaboration with clinics and diabetes communities. The company's revenues are based on the sale of automated insulin pumps. Seamless device assembly is ensured through the diversification of bioplastic and electronics suppliers.
BBNX (Beta Bionics Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Monitoring real yield per share is critical for minimizing risks during long-term asset ownership. By analyzing the TTM net income per share, an investor evaluates the total annual profit divided by the number of shares, which allows for a comparison between the commercial success of the iLet Bionic Pancreas system and the actual value of a shareholder's stake in Beta Bionics Inc (BBNX).